

IMDRF 2023

23rd session

27-28 March 2023 | Brussels, Belgium

The IMDRF Management Committee (MC) welcomed 350+ professionals to Brussels who participated to the EU chaired sessions as follows:

Day 1 - Joint IMDRF / Stakeholder (DITTA-GMTA) Workshop - 27 March 2023

The life cycle of medical devices: the importance of post-market-related activities

Opening Remarks

Welcome addresses by the IMDRF, DITTA and GMTA chairs

[Andrzej Ryś](#), [Patrick Hope](#), [Janet Trunzo](#)

Scene Setter

[Thomas Linders](#), [Adrien Guenego](#)

Post-market surveillance and RWE

Lifecycle approach to medical devices

[Philippe Auclair](#), [Matthias Neumann](#)

Session 1 : Safety notices and Vigilance

This is a session to discuss how we can improve "Safety Notice & Vigilance" to be more efficient and effective for manufacturers, regulators and healthcare providers. Each stakeholder will present concerns and propose ideas to improve current situation and discuss at the panel session.

- Opportunities and challenges: Regulator's perspective - [Melissa Torres](#) and [Christophe Driesmans](#)
- Opportunities and challenges: Industry perspective - [Nicole Smith](#) and [Miang Tanakasemsub](#)
- Opportunities and challenges: Healthcare professional perspective - [You-kyoung Lee](#) and [Timothy Wilton](#)
- Panel discussion: Opportunities for improvement - moderated by [Paul Piscoi](#)

Session 2: Real World Evidence

This is a session on real world evidence aims to describe the means through which real world evidence can be gathered and validated and which are the appropriate uses of real-world evidence within a regulatory context.

- Status of Global Acceptance of RWD/RWE in regulatory activities and lessons learned from various regions - [Heather M. Colvin](#)
- RIVD perspective and examples of RWD/RWE - [Elodie Baumfeld Andre](#)
- How to incorporate real-world data sources into regulatory decision-making processes? - [Tom Melvin](#)
- Uses of real-world evidence - [Erin Cutts](#), [Sabina Hoekstra](#) and [Lyu Yunfeng](#)
- Panel Discussion - moderated by [Heather M. Colvin](#) and [Donal O'Connor](#)

Session 3: Criteria, methods, and strategies to monitor safety and performance of software

- PMS for software: apped if you do, apped if you don't - [Kees Maquelin](#)
- Challenges and opportunities in collecting or generating data for digital MDs - [Pat Baird](#)
- Common post-market issues faced with software and how to address them? - [Rolf Oberlin Hansen](#)
- Panel discussion moderated by [Nada Alkhatat](#) and [Jesús Rueda Rodríguez](#)

Session 4: Specific post-market considerations for AI MDs

- Monitoring of endpoints (surrogate and non-surrogate) - [Leo Hovestadt](#)
- Bias in the post-market phase - [Anindita Saha](#) and [Pat Baird](#)

- Change management - [Rama Sethuraman](#) and [Melissa Finocchio](#)
- PMS for AI software - [Lesley-Anne Farmer](#) and [Hae Ung Lee](#)
- Panel Discussion moderated by [Matthias Neumann](#) and [Jesús Rueda Rodríguez](#)

Closing Remarks

Day 2 - 28 March 2023

IMDRF Stakeholder Forum

Opening Remarks

Welcome and Introduction

[Commissioner Stella Kyriakides](#)

Regulatory Updates from IMDRF Management Committee and Official Observers

- Australia - [Tracey Duffy](#)
- Brazil - [Augusto Bencke Geyer](#)
- Canada - [David Boudreau](#)
- China - [Yuang Peng](#)
- European Union - [Nada Alkhatat](#)
- Japan - [Masahiro Takahata](#)
- Singapore - [Rama Sethuraman](#)

Regulatory Updates from IMDRF Management Committee and Official Observers

- South Korea - [Gyuhan Chae](#)
- United Kingdom - [Harriet Teare](#)
- United States of America - [Melissa Torres](#)
- Argentina (Official Observer) - [Mariela Aranda](#) and [Carolina Magnatti](#)
- World Health Organization (Official Observer) - [Irena Prat](#)

Progress Overview of IMDRF Work Items

- Adverse Event Terminology (USA / EU) - [Andrea Hanson](#)
- Good Regulatory Review Practices (USA / Singapore) - [Erin Cutts](#)
- Medical Device Cybersecurity Guide (USA / Canada) - [Daniel Yoon](#)
- Personalized Medical Devices (Australia) - [Tracey Duffy](#)
- Quality Management Systems (USA / EU) - [Melissa Torres](#)
- Regulated Product Submission (Canada / USA) - [Daniel Yoon](#)
- Software as a Medical Device (USA / Canada) - [Daniel Yoon](#)
- Good Machine Learning Practice (USA / UK) - [Melissa Torres](#)

Stakeholders Session

- African Medical Devices Forum (AMDF) - [Paulyne Wairimu](#)
- Asia-Pacific Economic Cooperation (APEC) - [Cheng-Ning Wu](#)
- Global Harmonization Working Party (GHWP) - [Xu Jinghe](#)
- Pan American Health Organization (PAHO) - [Alexandre Lemgruber](#)
- The Global Diagnostic Imaging, Healthcare ICT, and Radiation Therapy Trade Association (DITTA) - [Patrick Hope](#)
- Global Medical Technology Alliance (GMTA) - [Janet Trunzo](#)

Closing Remarks

[Andrzej Ryś](#)